Results 181 to 190 of about 4,260,168 (338)

Self-driving bioprinting laboratories. [PDF]

Biofabrication
Liu S, Kaur N, Song DH, Moses JC, Ozbolat IT.   +4 more
europepmc   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Recommendation for the review of biological reference intervals in medical laboratories

Clinical Chemistry and Laboratory Medicine, 2016
J. Henny, A. Vassault, Guilaine Boursier, I. Vukasović, Pika Meško Brguljan, Maria Lohmander, Irina Ghiţă, F. B. Andreu, C. Kroupis, L. Šprongl, M. Thelen, F. Vanstapel, T. Vodnik, W. Huisman, M. Vaubourdolle   +14 more
semanticscholar   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Evaluation of the reproducibility and performance characteristics of the Phagomagnetic separation-qPCR assay for rapidly detecting viable <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> in bovine milk and feces. [PDF]

Front Vet Sci
Grant IR, Sevilla IA, Molina E, Romero Martinez B, Lorente-Leal V, Thibault-Poisson VC, Cechova M, Köhler H.   +7 more
europepmc   +1 more source

Assuring the Quality of Next-Generation Sequencing in Clinical Microbiology and Public Health Laboratories

Journal of Clinical Microbiology, 2016
Amy S. Gargis, L. Kalman, I. Lubin
semanticscholar   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Advancing standardization of diagnostics and antimicrobial susceptibility testing for pathogenic mycoplasmas of livestock origin: insights from the MyMIC network. [PDF]

BMC Vet Res
Jaÿ M, Klose SM, Bottinelli M, Autio T, Becker CAM, Bokma J, Boland C, Boyen F, Catania S, Dudek K, Hurri E, Feberwee A, Gyuranecz M, Lysnyansky I, Manso-Silván L, Palau-Ribes FM, Ramirez AS, Ridley A, Spergser J, Vaz PK, Wawegama N, Wiegel J, Heuvelink AE, Overesch G, Gautier-Bouchardon AV, Tardy F.   +25 more
europepmc   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Importance of reviewing the package insert from gradient strip manufacturers. [PDF]

J Antimicrob Chemother
Wootton M, Davies L, Livermore DM, Boyd SE, MacGowan A, Kahlmeter G, Howe R.   +6 more
europepmc   +1 more source